Please assess the completion status of the following clinical trial:

Trial Title: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of persistent/chronic ITP for at least 3 months~* Average platelet count\< 30,000/µL (and none \> 35,000 unless as a result of rescue therapy) from at least 3 qualifying counts~Exclusion Criteria:~* Clinical diagnosis of autoimmune hemolytic anemia~* Uncontrolled or poorly controlled hypertension~* History of coagulopathy including prothrombotic conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fostamatinib Disodium (Type: EXPERIMENTAL): Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
- Placebo (Type: OTHER): Placebo tablet PO bid (morning and evening) over the course of 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).